Stabilizes hydroxyapatite structure
Induce osteoblast to secrete inhibitors of osteoclast
Slows progress of osteoporosis
Bisphosphonate Alendronate Etidronate Pamidronate Risedronate
Peptide hormone by thyroid gland
Decreases bone resorption
Decreases serum calcium and phosphate
Paget’s disease
Hypercalcemia
Osteitis deformans pathologic fracture
Mosaic lamellar bone pattern
Etidronate and pamidronate SE
Bone mineralization defect (lose effectiveness after 12 months)
GI distress including esophageal ulcers (aledronate)
Drug for OCP induced osteoporosis
Alendronate
Osteoporosis type of fx
Subcapital
Bisphosphonate indications
Paget disease
Postmenopausal osteoporosis
Alendronate is the DOC for steroid-induced osteoporosis